 |
 |
 |
 |
 |
 |
 |
||
|
Juvaris BioTherapeutics, Inc. today announced the Company will be presenting at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Tuesday, November 8, 2005 at the New York Palace Hotel in New York City. Martin D. Cleary, Juvaris' Co-Founder, Chairman and CEO, will provide an overview of the status of Juvaris' business and collaborations at 10:10a.m. EST in the Adams Room. In addition, he will explain new developments in the Company's Influenza A, Avian flu and HIV vaccine programs. About Juvaris Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create JuvImmuneTM, a single lipid-DNA complex, which as a single product will have utility in multiple cancer and infectious disease applications. The JuvImmuneTM product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants. When combined with disease-specific antigens, the technology creates JuvaVaxTM vaccines capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes. Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. Moreover, substantial immune responses have been induced following oral and intranasal administration. This system provides the opportunity to develop many disease-specific immunotherapy products, for which there are significant unmet medical needs. The Company encourages investment and partnering inquiries and can be reached at its website @ www.juvaris.com. Company Contact: |